Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=458 Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Carcinoma, Hepatocellular
Primary: Time to Progression (TTP) — 164; 112 days
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
Phase 2 N=117 Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity — 0; 0; 0 Participants
Phase 2 N=78 Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536
Phase 2 N=67 Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
Carcinoma, Hepatocellular
Primary: Tumour Stabilisation Rate — 5.3; 16.0; 8.7 percentage of patients
N/A N=76 Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Two Year Overall Survival — 65; 68 percentage of participants
Phase 2 N=54 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Biliary Tract Neoplasms · Liver Cancer · Hepatocellular Carcinoma
Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months
Phase 2 N=32 Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants
Phase 2 N=137 A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Hepatocellular Carcinoma (HCC)
Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants
N/A N=76 Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI
Hepatocellular Carcinoma
Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants
Phase 2 N=97 A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Assessment of the Dose Limiting Toxicities for the Napabucasin and Amcasertib Arm in Combination With Sorafenib for Phase IB — 0; 0; 0; 0 Dose limiting toxicities
Phase 3 N=720 Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival — 289; 259 Days
N/A N=77 Dose Escalation Study for Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
Phase 1 N=10 Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
Hepatocellular Carcinoma
Primary: Number of Adverse Events — 12; 2; 8; 4 events
Phase 2 N=27 Trial of TRC105 and Sorafenib in Patients With HCC
Hepatocellular Carcinoma
Primary: Number of Patients Who Experience Dose Limiting Toxicities by Dose Level — 1; 0 Participants
N/A N=29 Impact of Y90 Radiation Segmentectomy on HCC
Hepatocellular Carcinoma
Primary: Number of Participants With Local Tumor Response According to mRECIST — 26; 0; 0; 3 Participants
Phase 3 N=546 Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
Carcinoma
Primary: Overall Survival (OS) — 7.56; 7.33 Months
Phase 3 N=565 A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 9.17; 7.62 months — p=0.1391
Phase 2 N=146 A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
Liver Cancer · Hepatocellular Cancer
Primary: The Percentage of Patients With Local Control at 1 Year Post Treatment — 99 percentage of patients
Phase 2 N=54 Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant
Hepatocellular Carcinoma · HCC
Primary: Freedom From Progression Over Time — 0; 3.4; 0; 26.5 percentage of patients with progression
Phase 2 N=21 Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants Who Remained Free of Progression at the 27th Week. — 21 participants — p=0.0006
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Phase 2 N=41 Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Liver Cancer
Primary: Response Rate by Recist Criteria — 6 participants
Phase 2 N=137 A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Percentage of Participants for Each Type of Response — 0; 2.2; 5.8; 54.7 percentage of participants
Phase 2 N=27 Sorafenib and TRC105 in Hepatocellular Cancer
Hepatoma · Liver Neoplasms · Adenoma, Liver Cell
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg
Phase 2 N=29 Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Median Time to Progression (TTP) — 3.7 months
N/A N=412 FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis
Liver Fibrosis · Cirrhosis · Chronic Hepatitis B
Primary: The Clinical Value Evaluation of FibroTouch for Non-invasive Diagnosis of Liver Fibrosis in Patients With Chronic Hepatitis B by Using Liver Pathology as the Gold…
N/A N=70 Sharing Decision-making Program for HCC Patients Treatment Decisions
Hepatocellular Cancer
Primary: Decisional Conflict Scale — 6.9; 11 score on a scale — p=0.05
Phase 2 N=19 A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Dose Limiting Toxicity — 0; 0; 0 Participants